Skip to content

AI-driven drug discovery and personalized medicine: integrating quantum computing and next-generation technologies

Sep 2026 · Quantum Machine Intelligence · Vol 8 · 0 citations · 90 references

TL;DR

A structured view of current advances, persistent gaps, and future directions in AI-enabled pharmaceutical innovation is offered, showing growing convergence between AI and precision therapeutics, but real-world application demands robust validation, collaboration, explainable AI, and global standards.

View source

Similar papers

Review Sep 2026

Precision Drug Discovery in the Era of Artificial Intelligence: A Critical Review.

A paradigm shift toward autonomous scientific agents capable of causal reasoning and end-to-end experimental guidance is highlighted, and persistent challenges are discussed, including data bias, limited interpretability, and in silico-to-wet lab translation.

Meng Liu, Jia-Cheng Xiong, Ming-Yue Zheng · 0 citations
Review 2026

Artificial Intelligence in Drug Discovery: Translational Bottlenecks, Biomedical Engineering Constraints, and Commercial Realities

The analysis suggests that AI will become an increasingly important component of pharmaceutical workflows; however, long-term impact will depend less on algorithmic advancement alone and more on effective integration with biological validation, experimental rigor, clinical evidence, and scalable translational infrastru...

Andrew Matelis · 0 citations
Review Sep 2026

AI-driven drug repurposing: Methods, platforms, and translational applications.

The conventional drug discovery pipeline is resource-intensive, time-consuming, and characterized by high attrition rates, often requiring more than a decade and billions of dollars to bring a single therapeutic agent to market. Drug repurposing identifying new therapeutic indications for approved or investigational dr...

Z. Malik, Kamran Ahmad, Sheheryar Ahmed · 0 citations
Review Open access Sep 2026

Artificial intelligence-assisted lead optimization in drug discovery: bridging computational advances and translational challenges.

It is concluded that future progress will depend less on increasingly sophisticated algorithms than on trustworthy AI systems that improve scientific decision-making within iterative lead optimization workflows and ultimately enhance translational success in drug discovery.

F. A. Mohamed, A. M. K. El-sagheir · 0 citations
Review Open access 2026

An AI platform to accelerate drug discovery: integrating target discovery, molecular generation, and simulation

This invited narrative review and platform perspective summarizes the concept and current implementation of an integrated Drug Discovery DX Platform (DXPF) that connects disease information and patient omics data to target gene/protein discovery, lead compound generation, and simulation-based evaluation.

Yasushi Okuno · 0 citations

Related blog posts

MIT News · Artificial Intelligence Oct 15, 2026

AI model decodes the language cells use to communicate

A new computational approach reveals how cells communicate to assemble into tissues. This could accelerate stem cell engineering, improve disease models, and inform therapies.

We use cookies to run the site and, with your consent, for analytics and to show ads. See our Cookie Policy.